In 2024, a case series published in PubMed Central documented something that should have sent shockwaves through the oncology world. Three patients with advanced cancer — breast, prostate, and melanoma — had taken fenbendazole, a veterinary deworming drug that costs less than a dollar per dose. Two achieved complete remission. The third achieved near-complete remission. The response from the medical establishment was not to fund a clinical trial. It was to explain why they should not have to.
The Man Who Was Supposed to Die
Joe Tippens was diagnosed with terminal small cell lung cancer in 2016. Doctors gave him months. He began taking fenbendazole — a drug designed to rid dogs of intestinal parasites — alongside a protocol he shared publicly online. Eight years later, Tippens is still alive. In February 2026, he appeared at the Annie Appleseed Conference, cancer-free and speaking to a room full of people who had followed his journey. The establishment is quick to note that Tippens was simultaneously enrolled in a Keytruda immunotherapy trial, as if this detail alone invalidates the broader question. But does it answer it? If a man on the brink of death takes two things and survives, is the scientific response really to dismiss one of them without investigation?
The Science Nobody Wanted to Fund
The preclinical evidence for fenbendazole is not anecdotal. It is published, peer-reviewed, and growing. Studies have demonstrated activity against cervical cancer, ovarian cancer, colorectal cancer, and breast cancer in laboratory models. The mechanisms are well-documented: fenbendazole induces pyroptosis, triggers apoptosis, causes G2/M cell cycle arrest, and targets cancer stem cells — the very cells thought to drive recurrence and metastasis. A 2025 study combining fenbendazole with dichloroacetate showed 50 percent complete tumor regression in a lung cancer mouse model, compared to zero percent in the control group. EUCLID University published a paper titled “The Urgent Need for Clinical Studies to Evaluate Anti-Tumor Efficacy of Fenbendazole.” The word “urgent” appeared in the title of an academic paper, and still nothing happened.
170 Stories That Don’t Count
Between 2023 and 2025, at least 170 anecdotal reports of tumor regression across various cancers were compiled from patients taking fenbendazole protocols. Facebook groups with over 100,000 members now exist where people share dosing schedules, bloodwork, and imaging results. These are not clinical trials. They are not controlled. But they represent something that the medical system has consistently failed to provide: a reason to look closer. When 100,000 people gather online around a veterinary drug because they believe it is saving their lives, the question is not whether they are right. The question is why no one with the resources to find out has bothered to ask.
The Barrier That Isn’t One
The most commonly cited obstacle to clinical trials is fenbendazole’s “poor water solubility” — a pharmacological limitation that, in theory, makes it difficult to deliver therapeutic doses in humans. And yet patients are taking it orally. They are reporting results. Published case studies document remission. If the drug cannot work because of solubility issues, then what exactly happened in those PubMed cases? If it can work despite solubility issues, then the barrier is not scientific. It is financial. Fenbendazole cannot be patented. It cannot generate the revenue stream required to justify the hundreds of millions a pharmaceutical company would spend on Phase III trials. And so it sits — effective enough to publish about, cheap enough to ignore.
What Does It Mean?
A drug that costs pennies produced complete remission in published case studies. It has demonstrated anticancer activity across multiple tumor types in preclinical research. A man given months to live took it and survived for nearly a decade. The scientific community responded not with curiosity, but with caution — the kind of caution that looks remarkably like indifference when you are the patient running out of options. The question was never whether fenbendazole deserves a trial. The question is who benefits from making sure it never gets one.
